Dear All, In a thoughtful companion to WHO’s preclinical and clinical pipeline reviews, we now have an instructive analysis of the global funding pipeline for 2017-2023! Here are the links you need: The new paper and its primary data source: Paper: Czaplewski L, Lamichhane U, Sudbrak R, Hennessy A, Ogilvie LA, and Piddock LJV. An
Dear All, I just today learned that FDA has posted two antimicrobial resistance-related (AMR-related) FY 2026 funding opportunities. The titles for the RFPs are very good descriptions of each and I’ve added a few details from the RFPs: Request for Proposals to Facilitate Development of Susceptibility Test Interpretive Criteria (STIC or Breakpoints) for Candida auris
Dear All (wonkish … but worth it … get ready to follow the links!), Greetings in the new year! As a marvelous way to end the last year, the US FDA announced on 12 Dec 2025 its approval of two new oral therapies for gonorrhea, thus addressing the priority pathogen lists of both WHO (High
Dear All, Happy New Year! As a great start for January, Team CARB-X have announced (i) that they will have two funding calls during 2026 (April and then Q4) and (ii) that a theme focused on finding new chemical scaffolds will be part of both calls. Applications to these target-based therapeutics funding calls will require defined chemistry
Dear All, Regular readers will be aware of the global conversation now happening around the threat arising from the potential to create viable organisms that are (at a molecular level) the mirror images of existing organisms. If this is new to you (or, if you’d like a refresh), here are the links you need: 18
Dear All, In a paper that is clearly a labor of love (1,032 references!), Mark Butler and Robert Capon have summarized the history of 217 natural product-inspired antibiotics across 16 classes from penicillin to fidaxomicin! Here are the links you need: Butler MS, Capon RJ. Natural product inspired antibiotics approved for human use – 1943
Dear All, Our colleagues in Europe have been busy! Along with yesterday’s announcement about transferrable exclusivity vouchers, we also had publication of the Horizon Europe Work Programme 2026-2027. It’s a really big program that includes within its Cluster 1 a trio of calls of interest to readers of this newsletter: HORIZON-HLTH-2027-01-DISEASE-08 call seeks projects developing
Dear All, There are more details yet to come, but the EU Council (“the Council”) and the EU Parliament (EP) yesterday announced an agreement on the update to the EU General Pharmaceutical Legislation that includes transferable exclusivity vouchers (TEVs or TEEVs, depending on your preferred abbreviation). Here’s the key text from the EP’s press release:
Note: As always, please use the copy of the newsletter posted at https://amr.solutions/ if you have trouble with links in this newsletter. Dear All, As I hope you know from the meeting calendar in this newsletter, the 2nd edition of GAMRIC, the Global AMR Innovators Conference, will be 22-24 Sep 2026 in Lisbon, Portugal. Although only the 2nd year
Dear All, The 8 Dec 2025 newsletter entitled “Phage therapy: Regulatory perspectives from TATFAR” generated a fair bit of commentary! I’ve now added several post-newsletter addenda to the online copy of the newsletter and I thought the amount of new material warranted a summary of same via this follow-up newsletter. If I’ve missed a resource,